Savara to Present Phase 3 IMPALA-2 Trial Data and Host aPAP Symposium at ERS Congress 2025
核心洞察
Savara Inc. will present three research abstracts at the European Respiratory Society Congress 2025, including new data from the Phase 3 IMPALA-2 trial of inhaled molgramostim for autoimmune pulmonary alveolar proteinosis (搜索).
The presentations will showcase findings on disease burden, treatment efficacy across varying severity levels, and the relationship between pulmonary function and quality of life in aPAP (搜索) patients.
Partner company TrilliumBiO (搜索) will introduce a new dried serum assay for detecting GM-CSF antibodies to improve diagnostic accuracy for aPAP (搜索).
Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, taking place September 27 to October 1 in Amsterdam, The Netherlands. The company will also host an Industry Evening Mini Symposium focused on advances in autoimmune pulmonary alveolar proteinosis (搜索) (aPAP (搜索)).
Phase 3 IMPALA-2 Trial Results
One of the key presentations will feature new data from Savara's Phase 3 IMPALA-2 trial examining the efficacy of inhaled molgramostim according to severity of autoimmune pulmonary alveolar proteinosis (搜索). Dr. Cormac McCarthy, Associate Professor of Medicine at University College Dublin and Consultant Respiratory Physician at St. Vincent's University Hospital, will present findings on how the treatment performs across varying levels of disease severity.
Disease Burden and Quality of Life Research
Dr. Francesco Bonella, Head of the Center for Interstitial and Rare Lung Diseases at Ruhrlandklinik University Hospital in Essen, Germany, will present research exploring the relationship between pulmonary gas transfer, respiratory health-related quality of life, exercise capacity, and surfactant burden in aPAP (搜索) patients. This study aims to better understand the comprehensive impact of the disease on patient outcomes.
Diagnostic Advancement
Savara's partner TrilliumBiO (搜索) will contribute to the scientific program with the presentation of a new diagnostic tool. Dr. Eagappanath Thiruppathi, Director of Test and Method Development at TrilliumBiO, will introduce a dried serum assay designed to detect GM-CSF antibodies, which is expected to improve diagnostic accuracy for aPAP (搜索).
Industry Symposium on aPAP Advances
Beyond the poster presentations, Savara will host an Industry Evening Mini Symposium on September 29, titled "Advances in Autoimmune Pulmonary Alveolar Proteinosis (搜索)." The session will feature comprehensive updates on disease pathophysiology, signs and symptoms, burden of illness, and evolving treatment strategies.
The symposium will include presentations from leading international experts:
- Dr. Effrosyni D. Manali from the National and Kapodistrian University of Athens
- Dr. Maria Molina-Molina from Hospital Universitario de Bellvitge, Spain
- Dr. Maria Kokosi from Royal Brompton Hospital, London
Brian Robinson, M.D., Executive Vice President of Global Medical Affairs at Savara, will chair the session.
Clinical Impact and Future Directions
All three poster presentations are scheduled for the same session (PS-37 / Interstitial Lung Diseases / Respiratory Critical Care / Alveolar Filling Disorders and Autoimmune Lung Diseases) on Monday, September 29, 2025, from 8:00 to 9:30 CEST at RAI Amsterdam.
By presenting these studies and leading discussions at ERS 2025, Savara aims to strengthen awareness and advance clinical understanding of autoimmune pulmonary alveolar proteinosis (搜索). The company's research highlights its commitment to improving diagnostics and treatment strategies for patients with this rare and often misunderstood disease.